Trial reportClinical ophthalmology (Auckland, N.Z.)2026
Safety and Effectiveness of Iota-Carrageenan Eye Drops for the Treatment of Dry Eye Disease.
Trial report in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06262100 (Clinical Investigation to Evaluate the Lubricating Performance of Carragelose Containing Eye Drops in Patients Diagnosed with Mild-to-moderate Dry Eye Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Investigation to Evaluate the Lubricating Performance of Carragelose Containing Eye Drops in Patients Diagnosed with Mild-to-moderate Dry Eye Disease
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This clinical investigation evaluated the safety and effectiveness of iota-carrageenan (I-C) eye drops in adults with mild-to-moderate dry eye disease (DED). Methods: In this prospective, single-arm, open-label study, 30 participants applied I-C eye drops three times daily for four weeks. Symptoms (foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision, photophobia) were assessed before and after treatment under both normal controlled environment (NCE) and adverse controlled environment (ACE) conditions. Secondary endpoints included Ocular Surface Disease Index (OSDI), CDES-Q, corneal and conjunctival damage, tear film break-up time, tear evaporation, and tear production. Tolerability was self-reported, while safety (including visual acuity and intraocular pressure) was monitored throughout. Results: After four weeks, mean total DED score decreased significantly by -11.89 points after ACE (95% CI: -15.11, -8.67; p<0.001) and by -8.07 points after NCE (95% CI: -10.71, -5.43; p<0.001). Symptom improvement was observed in 93% (ACE) and 89% (NCE) of participants. Mean OSDI score decreased by -7.75 points (95% CI: -10.85, -4.63; p<0.001). Treatment reduced ACE-induced tear film instability and ocular surface damage. All adverse events were mild and transient; 93% of participants rated tolerability as good or very good. No safety concerns were identified. Conclusion: I-C eye drops are safe, well tolerated, and effective in alleviating DED symptoms, improving tear film stability, and protecting the ocular surface, including under adverse environmental conditions. Trial Registration: NCT06262100.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.